A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).

CT.gov Identifier
NCT07807995
EudraCT Identifier
N/A
CTIS:
2025-525064-14-00
Sponsor
Vertex Pharmaceuticals
Collaborator
N/A
Study Contact Information
+1 617 341 6100
Recruiting
Contact Us

Study Details

Diseases
IgA nephropathy
Study Drug
Povetacicept
Genes
N/A
Study Dates
Sep 2026 - Dec 2029
Sex
Female & Male
Age
18+ years
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • * Completed the Week 104 visit in the parent study VX24-AIS-D08 (NCT06564142) and has not permanently discontinued study drug
  • * Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 15 milliliters per minute (mL/min)/1.73 square meter (m^2) within 45 days of Day 1 of this study
  • Key
Exclusion Criteria:
  • \- Planned participation in another interventional, therapeutic clinical trial (other than the parent study).
  • Other protocol defined Inclusion/Exclusion criteria may apply.

Protocol Summary

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.